Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Medopad, a UK Healthcare App, Signs $140 Million of Deals in China

publication date: Feb 1, 2018

Medopad, a UK AI mobile healthcare app, signed 15 contracts with China companies that have a total value of over $140 million. Medopad combines AI with patient records for doctors and remote monitoring among its many services. The partnerships included a collaboration with Tencent Holdings to use AI to support doctors’ decision-making, plus other agreements with China Resources, Ping An Good Doctor, Peking University, Lenovo New Vision and GSK China. Medopad officials were part of a UK trade mission to China led by Prime Minister Theresa May. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital